We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Oyster Point Pharma, Inc. (“Oyster Point” or the “Company”) (NASDAQ: OYST), in connection with the proposed acquisition of the Company by Viatris Inc. (NASDAQ: VTRS) via tender offer.  Under the terms of the merger agreement, the Company’s shareholders will receive $11.00 in cash for each share of Oyster Point common stock owned, plus a contingent value right (“CVR”) representing the right to receive a potential cash payment of up to $2.00 per share.

Weiss Law is investigating whether (i) Oyster Point’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $11.00 per-share merger consideration adequately compensates Oyster Point’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.  Notably, the merger consideration is below the $21 median price target set by analysts, and at least one analyst set a price target for the Company of $65 per share, $54.00 above the per-share merger consideration.